Ventas, Inc.
NYSE:VTRREIT - Healthcare Facilities
-$0.28 today
- Market cap
- $46.64B
- Beta
- 0.73
- P/E (TTM)
- 149.7
- EPS (TTM)
- $0.55
- Dividend yield
- 2.39%
Volume 3.72M
Average 4.09M
VTR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ventas, Inc.NYSE: VTR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $631.58M rose 17.3% year over year, behind the +27.0% change in trailing-twelve-month EBITDA. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- EBITDA amounted to 38.4% of revenue in FY2025, up 1.4 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of $2.05B (-8.2%) for the fiscal year ending Dec 2026, a slowdown from the +23.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $631.58M-13.5% QoQ
- Last fiscal yearDec 2025
- $2.24B+23.0% YoY
- LTMJun 2026
- $2.48B+27.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +17.3% | +27.1% | +9.8 pp |
| 1 year | +23.0% | -8.2% | -31.2 pp |
| 3-year CAGR | +14.3% | -3.3% | -17.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 2.24B USD
- Year-over-year change
- +23.0%
- 4-year CAGR
- +10.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.24B | +23.0% |
| FY2024 | 2024-12-31 | 1.82B | +7.1% |
| FY2023 | 2023-12-31 | 1.7B | +13.4% |
| FY2022 | 2022-12-31 | 1.5B | +1.4% |
| FY2021 | 2021-12-31 | 1.48B | — |
EBITDA vs competitors
How VTR compares with its peers on the latest reported figures
- VTR's LTM Jun 2026 EBITDA of $2.48B is the 2nd highest of the 11 companies compared; the peer median is $725.13M.
- Its year-over-year change of +27.0% is the 7th highest of 10, against a peer median of +45.6%.
- EBITDA amounts to 38.5% of revenue for VTR, versus a peer median of 83.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.33B | -5.4% | +4.2% | 24.3% | |
| LTM Jun 2026 | $2.48B | +27.0% | +14.3% | 38.5% | |
| LTM Sep 2026 | $1.76B | +15.8% | +1.1% | 78.5% | |
| LTM Jun 2026 | $1.45B | +41.6% | +5.3% | 112.1% | |
MPTMedical Properties Trust, Inc. | LTM Jun 2026 | $1.05B | +979.1% | -31.2% | 103.2% |
| LTM Sep 2026 | $851.29M | +205.9% | +16.4% | 186.2% | |
| LTM Sep 2026 | $598.98M | +449.6% | +5.2% | 152.0% | |
| LTM Sep 2026 | $547.75M | +45.6% | +85.1% | 89.0% | |
| LTM Sep 2026 | $482.47M | +49.6% | +15.4% | 18.1% | |
| LTM Jun 2026 | $390.9M | -17.8% | +28.2% | 45.5% | |
NHPNational Healthcare Properties, Inc. (NHP) | LTM Dec 2025 | $84.36M | — | +14.7% | 24.6% |
| Peer median (excluding VTR) | $725.13M | +45.6% | +10.0% | 83.8% | |
Competitors are the stored peer set for VTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.83B | 4.13B | 4.5B | 4.92B | 5.83B |
| Cost of Revenue | 2.09B | 2.28B | 2.56B | 2.83B | 6.18B |
| Gross Profit | 1.74B | 1.85B | 1.94B | 2.1B | (344.22M) |
| Gross Margin | 45.4% | 44.7% | 43.1% | 42.6% | -5.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 129.76M | 144.87M | 148.88M | 162.99M | 177.4M |
| Operating Expenses | 1.32B | 1.36B | 1.52B | 1.42B | (1.17B) |
| Depreciation & Amortization | 978M | 1.09B | 1.17B | 1.17B | 1.38B |
| EBITDA | 1.48B | 1.5B | 1.7B | 1.82B | 2.24B |
| EBITDA Margin | 38.6% | 36.3% | 37.8% | 37.0% | 38.4% |
| Operating Income | 421.43M | 483.85M | 415.51M | 681.23M | 826.81M |
| Operating Margin | 11.0% | 11.7% | 9.2% | 13.8% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 22.59M |
| Interest Expense | 440.09M | 467.56M | 574.11M | 602.84M | 612.25M |
| Other Income / Expenses | (360.05M) | (541.7M) | (455.35M) | (630.65M) | (579.44M) |
| Income Before Tax | 61.39M | (57.86M) | (39.84M) | 50.58M | 247.37M |
| Pre-Tax Margin | 1.6% | -1.4% | -0.9% | 1.0% | 4.2% |
| Income Tax Expense | 4.83M | (16.93M) | (9.54M) | (37.78M) | (14.15M) |
| Net Income | 49.01M | (47.45M) | (40.97M) | 81.15M | 251.38M |
| Net Margin | 1.3% | -1.1% | -0.9% | 1.6% | 4.3% |
| EPS (Basic) | 0.13 | (0.13) | (0.10) | 0.20 | 0.55 |
| EPS (Diluted) | 0.13 | (0.13) | (0.10) | 0.19 | 0.54 |
| Weighted Avg Shares | 382.79M | 373.37M | 401.81M | 411.77M | 455.08M |
| Weighted Avg Shares (Diluted) | 386.3M | 373.37M | 405.67M | 416.37M | 462.62M |
Ventas, Inc.
NYSE:VTR
Intrinsic Alpha fair value
Locked
Current Price
$88.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.